Sanara MedTech (SMTI) furnishes Q2 2026 financial results press release

Rhea-AI Filing Summary

Sanara MedTech Inc. reported that it issued a press release on August 11, 2026 announcing its financial results for the quarter ended June 30, 2026. The press release is included as Exhibit 99.1 to this current report and is treated as information furnished rather than filed under the Exchange Act.

Key Terms

Emerging growth company, furnished, Inline XBRL

3 terms

Emerging growth company regulatory

"Emerging growth company"

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

furnished regulatory

"press release is furnished as Exhibit 99.1"

Inline XBRL technical

"Cover Page Interactive Data File (embedded within the Inline XBRL document)"

Inline XBRL is a file format for financial filings that embeds machine-readable data tags directly inside the human-readable report, so the same document can be read by people and parsed by software. For investors it makes extracting, comparing and verifying financial numbers faster and more reliable—like a grocery list where each item also has a barcode—reducing manual errors and speeding up analysis.

Earnings Snapshot

quarter ended June 30, 2026

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/11/2026 - 04:35 PM Accepted by SEC EDGAR 08/11/2026 - 04:11 PM Learn about SEC filing dates

FAQ

What did Sanara MedTech Inc. (SMTI) disclose in the August 11, 2026 current report?

Sanara MedTech Inc. disclosed that it issued a press release announcing financial results for the quarter ended June 30, 2026, which is included as Exhibit 99.1 and furnished, not filed.

Which period do the latest Sanara MedTech (SMTI) results in this report cover?

The results described relate to the quarter ended June 30, 2026. Detailed financial figures are contained in the accompanying press release furnished as Exhibit 99.1 to the current report.

How are Sanara MedTech’s (SMTI) August 11, 2026 financial results treated under securities laws?

The financial results press release is furnished, not filed, under the Exchange Act. This means it is not subject to Section 18 liability or automatically incorporated into other securities filings.

Where can investors find the detailed Q2 2026 results for Sanara MedTech (SMTI)?

Detailed figures are included in Exhibit 99.1, the press release issued August 11, 2026. The current report states that this exhibit contains the company’s financial results for the quarter ended June 30, 2026.

What exhibits accompany Sanara MedTech’s (SMTI) August 11, 2026 current report?

The report includes Exhibit 99.1, a press release with Q2 2026 financial results, and Exhibit 104, a cover page interactive data file embedded within the Inline XBRL document.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 11, 2026

SANARA MEDTECH INC.

(Exact name of registrant as specified in its charter)

Texas		001-39678		59-2219994
(State or other jurisdiction		(Commission		(IRS Employer
of incorporation)		File Number)		Identification No.)

1200 Summit Avenue, Suite 414 Fort Worth, Texas		76102
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (817) 529-2300

(Former name or former address, if changed since last report)

Not Applicable

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

	☒	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
	☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
	☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
	☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.001 par value		SMTI		The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On August 11, 2026, Sanara MedTech Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2026. A copy of the Company’s press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.

The information in this Current Report on Form 8-K, including Exhibit 99.1 furnished hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Press Release issued August 11, 2026 (furnished pursuant to Item 2.02).
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date:	August 11, 2026
		Sanara MedTech Inc.
		By:	/s/ Elizabeth B. Taylor
		Name:	Elizabeth B. Taylor
		Title:	Chief Financial Officer